Charles Bennett to Evidence-Based Medicine
This is a "connection" page, showing publications Charles Bennett has written about Evidence-Based Medicine.
Connection Strength
0.364
-
Acting on imperfect evidence: How much regret are we ready to accept? J Clin Oncol. 2005 Oct 01; 23(28):6822-5.
Score: 0.199
-
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999 Sep 01; 94(5):1517-36.
Score: 0.033
-
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). 1999 May; (4):i-x, 1-246, I1-36, passim.
Score: 0.032
-
Failure to place evidence at the centre of quality improvement remains a major barrier for advances in quality improvement. J Eval Clin Pract. 2019 06; 25(3):369-372.
Score: 0.032
-
The 2018 ISDE achalasia guidelines. Dis Esophagus. 2018 Sep 01; 31(9).
Score: 0.031
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008 Jan 01; 26(1):132-49.
Score: 0.014
-
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 01; 24(19):3187-205.
Score: 0.013
-
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002 Oct 01; 100(7):2303-20.
Score: 0.010